More on PPCB

- Summary
- Chart
- Profile
- Historical

Data

- Earnings

Upcoming Events

- Earnings (1/2/26 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Propanc Biopharma, Inc. (NQ:PPCB)
Delayed: 0.51 +0.01 (2.00%)
Prev. Close $0.50  
Open$0.51 
52 Wk High$ 
52 Wk Low$ 
Day High$0.53 
Day Low$0.50 
P/E N/A  
EPS$ 
Volume72,202 

Friends, Peers and Foes (?): RVMD (more...)

Sep 29, 2026 08:32 AM Propanc Biopharma plans Phase 1b cancer trial, posts $18.9M net loss
Sep 29, 2026 08:30 AM Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
Sep 29, 2026 08:30 AM Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
Sep 25, 2026 05:09 PM Form 10-K Propanc Biopharma, Inc. For: Jun 30
Sep 22, 2026 08:31 AM Propanc releases preclinical PDAC data for PRP, eyes 2027 trial
Sep 22, 2026 08:30 AM Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
Sep 16, 2026 08:30 AM Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
Sep 9, 2026 08:30 AM Propanc Biopharma plans Phase 1b cancer drug trial for February 2027
Sep 9, 2026 08:30 AM Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027
Aug 27, 2026 08:30 AM Propanc reports preclinical pancreatic cancer data for PRP drug candidate
View All Articles

Entities mentioned with PPCB

View All Entities